Evaluation of Е-cadherin expression in invasive ductal breast cancer
Wiadomości Lekarskie · 27.02.2026 · (2) · 255-264
DOI: 10.36740/wlek/218713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wiadomości Lekarskie, online erschienen am 27.02.2026. Verfasst von Ilona V Chelpanova und 6 weiteren Autor:innen. Beteiligte Einrichtung: STATE NON-PROFIT ENTERPRISE «DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY», LVIV, UKRAINE. Hauptthemen laut MEDLINE: Cadherins, Breast Neoplasms, Carcinoma, Ductal, Breast.
Abstract (Originalsprache)
Aim
To evaluate E-cadherin expression in various clinical and pathological prognostic scenarios to determine its significance in the development of molecular subtypes of invasive ductal breast cancer. Materials and Methods: A comprehensive morphological and immunohistochemical study of 80 cases of invasive ductal carcinoma (IDC) was conducted to determine the molecular phenotype. The expression of E-cadherin, ER, PR receptors, c-erbB2, and Ki-67 was evaluated according to the manufacturer’s standardized protocols using appropriate positive and negative controls. The degree of tumor malignancy was determined using the modified Scarff-Bloom- Richardson system. Semi-quantitative assessment of E-cadherin expression was performed using the Qureshi scale. Pearson’s criterion was used for statistical analysis. Differences were considered statistically significant at p < 0.05.
Results
Low E-cadherin expression was associated with stage 3, pT3, and G2/G3 grades of IDBC malignancy, confirming its unfavorable prognostic significanc and correlation with the molecular profile. High E-cadherin expression was characteristic of ER-positive luminal A tumors, regardless of menopause, indicating a regulatory role for ER expression. The low proliferative activity of luminal IDBC cells was explained by high E-cadherin expression, which increased adhesive properties. Low E-cadherin expression is also a prognostic marker for TNBC.
Conclusions
E-cadherin is a potent tumor suppressor in breast cancer. Its role in disease progression is confirmed by the correlation between partial or complete loss of E-cadherin expression and poor prognosis for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- STATE NON-PROFIT ENTERPRISE «DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY», LVIV, UKRAINE.
- WESTERN UKRAINIAN HISTOLOGICAL LABORATORY, LVIV, UKRAINE.
- INTERNATIONAL MEDICAL CENTER LLC, KYIV, UKRAINE.
Zitieren
APA
Chelpanova, I. V., Volos, L. I., Dudash, A. P., Paltov, Y. V., Poliiants, A. V., Dudok, O. V., & Hnidyk, Y. V. (2026). Evaluation of Е-cadherin expression in invasive ductal breast cancer. Wiadomości Lekarskie, 255-264. https://doi.org/10.36740/wlek/218713
Vancouver
Chelpanova IV, Volos LI, Dudash AP, Paltov YV, Poliiants AV, Dudok OV, et al. Evaluation of Е-cadherin expression in invasive ductal breast cancer. Wiadomości Lekarskie. 2026:255-264. doi:10.36740/wlek/218713
BibTeX
@article{Chelpanova2026,
author = {Chelpanova, Ilona V and Volos, Liliya I and Dudash, Andrii P and Paltov, Yevgen V and Poliiants, Artur V and Dudok, Olha V and Hnidyk, Yulia V},
title = {Evaluation of Е-cadherin expression in invasive ductal breast cancer},
journal = {Wiadomości Lekarskie},
year = {2026},
number = {2},
pages = {255--264},
doi = {10.36740/wlek/218713}
}
EUVIMED